Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer
Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer
复制标题
YES1 过度表达与上皮性卵巢癌患者的良好预后和铂敏感性增加相关
DOI：
10.14670/hh-18-203
复制
发表时间：
2020-07-01
影响因子：
2
通讯作者：
Zheng, Min
中科院分区：
文献类型：
--
作者：
Zhou, Yun;Chen, Ping;Zheng, Min
目标。YES1在上皮性卵巢癌（EOC）中的预后应用目前尚不清楚。我们的目的是研究YES1在EOC患者中的表达及其与生存结局的关系。方法。对2002年至2013年在中国广州中山大学癌症中心诊断为EOC的患者进行回顾性研究。采用组织芯片检测YES1的免疫组化表达。生存率采用Kaplan-Meier法分析，组间比较采用log-rank检验。采用Cox比例风险模型进行多变量分析。结果。共有132例EOC患者入组。yes1高组患者的OS和PFS明显优于yes1低组（P=0.02和P=0.03）。进一步的单因素和多因素回归分析表明YES1是EOC患者OS的独立预后因素。值得注意的是，YES1高表达组中铂敏感组有40例（74.1%），铂耐药组有14例（25.9%）重叠。相反，在YES1低表达组中，铂敏感11例（47.8%），铂耐药12例（52.2%）。总体而言，YES1高表达组患者对铂类化疗的敏感性明显高于YES1低表达组（P=0.03），且YES1水平在铂类敏感组持续且显著升高。结论。YES1在EOC患者组织中的高细胞质表达与良好的预后显著相关。YES1高表达的患者对铂类化疗更敏感。
Aims. The prognostic application of YES1 in epithelial ovarian cancer (EOC) is currently unclear. We aimed to investigate the expression of YES1 and its correlation with survival outcome in patients with EOC. Methods. A retrospective study of patients diagnosed with EOC at the Cancer Center, Sun Yat-Sen University, Guangzhou, China between 2002 and 2013 was conducted. The immunohistochemical expression of YES1 was assessed using tissue microarray. Survival rates were analyzed by the Kaplan-Meier method and were compared between groups using the log-rank test. Multivariate analyses were performed using the Cox proportional hazards model. Results. A total of 132 patients with EOC were enrolled. Patients in the YES1-high group exhibited significantly better OS and PFS, compared with those in the YES1-low group (P=0.02 and P=0.03, respectively). Further univariate and multivariate regression analyses indicated YES1 as an independent prognostic factor for the OS of patients with EOC. Notably, within the high YES1 expression group, 40 cases (74.1%) were of the platinum-sensitive group while 14 (25.9%) overlapped were of the platinum-resistant group. Conversely, in the low YES1 expression group, 11 cases (47.8%) were platinum-sensitive, and 12 (52.2%) platinum-resistant. Overall, patients within the high YES1 expression group were deemed significantly more sensitive to platinum-based chemotherapy than the low YES1 expression group (P=0.03), and YES1 levels were consistently and significantly higher in the platinum-sensitive group. Conclusions. High YES1 cytoplasmic expression in EOC patient tissue is significantly correlated with favorable prognosis. Patients with high YES1 expression tend to be sensitive to platinum-based chemotherapy.